Literature DB >> 19470513

Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.

Christopher S Lunde1, Stephanie R Hartouni, James W Janc, Mathai Mammen, Patrick P Humphrey, Bret M Benton.   

Abstract

Telavancin is an investigational lipoglycopeptide antibiotic currently being developed for the treatment of serious infections caused by gram-positive bacteria. The bactericidal action of telavancin results from a mechanism that combines the inhibition of cell wall synthesis and the disruption of membrane barrier function. The purpose of the present study was to further elucidate the mechanism by which telavancin interacts with the bacterial membrane. A flow cytometry assay with the diethyloxacarbocyanine dye DiOC(2)(3) was used to probe the membrane potential of actively growing Staphylococcus aureus cultures. Telavancin caused pronounced membrane depolarization that was both time and concentration dependent. Membrane depolarization was demonstrated against a reference S. aureus strain as well as phenotypically diverse isolates expressing clinically important methicillin-resistant (MRSA), vancomycin-intermediate (VISA), and heterogeneous VISA (hVISA) phenotypes. The cell wall precursor lipid II was shown to play an essential role in telavancin-induced depolarization. This was demonstrated both in competition binding experiments with exogenous D-Ala-D-Ala-containing ligand and in experiments with cells expressing altered levels of lipid II. Finally, monitoring of the optical density of S. aureus cultures exposed to telavancin showed that cell lysis does not occur during the time course in which membrane depolarization and bactericidal activity are observed. Taken together, these data indicate that telavancin's membrane mechanism requires interaction with lipid II, a high-affinity target that mediates binding to the bacterial membrane. The targeted interaction with lipid II and the consequent disruption of both peptidoglycan synthesis and membrane barrier function provide a mechanistic basis for the improved antibacterial properties of telavancin relative to those of vancomycin.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19470513      PMCID: PMC2715647          DOI: 10.1128/AAC.01710-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  51 in total

1.  Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity.

Authors:  I Wiedemann; E Breukink; C van Kraaij; O P Kuipers; G Bierbaum; B de Kruijff; H G Sahl
Journal:  J Biol Chem       Date:  2000-10-18       Impact factor: 5.157

2.  Membrane potential estimation by flow cytometry.

Authors:  H M Shapiro
Journal:  Methods       Date:  2000-07       Impact factor: 3.608

3.  Reductive alkylation of glycopeptide antibiotics: synthesis and antibacterial activity.

Authors:  R D Cooper; N J Snyder; M J Zweifel; M A Staszak; S C Wilkie; T I Nicas; D L Mullen; T F Butler; M J Rodriguez; B E Huff; R C Thompson
Journal:  J Antibiot (Tokyo)       Date:  1996-06       Impact factor: 2.649

Review 4.  The emergence and evolution of methicillin-resistant Staphylococcus aureus.

Authors:  K Hiramatsu; L Cui; M Kuroda; T Ito
Journal:  Trends Microbiol       Date:  2001-10       Impact factor: 17.079

5.  Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics.

Authors:  D A Beauregard; D H Williams; M N Gwynn; D J Knowles
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

6.  Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria.

Authors:  T I Nicas; D L Mullen; J E Flokowitsch; D A Preston; N J Snyder; R E Stratford; R D Cooper
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

7.  Accurate flow cytometric membrane potential measurement in bacteria using diethyloxacarbocyanine and a ratiometric technique.

Authors:  D Novo; N G Perlmutter; R H Hunt; H M Shapiro
Journal:  Cytometry       Date:  1999-01-01

8.  Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50.

Authors:  L Cui; H Murakami; K Kuwahara-Arai; H Hanaki; K Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

9.  Multiparameter flow cytometric analysis of antibiotic effects on membrane potential, membrane permeability, and bacterial counts of Staphylococcus aureus and Micrococcus luteus.

Authors:  D J Novo; N G Perlmutter; R H Hunt; H M Shapiro
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

10.  Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic.

Authors:  E Breukink; I Wiedemann; C van Kraaij; O P Kuipers; H G Sahl; B de Kruijff
Journal:  Science       Date:  1999-12-17       Impact factor: 47.728

View more
  56 in total

1.  In vitro activity of telavancin in combination with colistin versus Gram-negative bacterial pathogens.

Authors:  Michael Hornsey; Christopher Longshaw; Lynette Phee; David W Wareham
Journal:  Antimicrob Agents Chemother       Date:  2012-04-09       Impact factor: 5.191

2.  Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents.

Authors:  Rodrigo E Mendes; Helio S Sader; David J Farrell; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2012-04-16       Impact factor: 5.191

Review 3.  Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.

Authors:  Biswadeep Das; Chayna Sarkar; Debasmita Das; Amit Gupta; Arnav Kalra; Shubham Sahni
Journal:  Ther Adv Infect Dis       Date:  2017-03-08

4.  Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing.

Authors:  Adam Belley; Geoffrey A McKay; Francis F Arhin; Ingrid Sarmiento; Sylvain Beaulieu; Ibthihal Fadhil; Thomas R Parr; Gregory Moeck
Journal:  Antimicrob Agents Chemother       Date:  2010-09-27       Impact factor: 5.191

5.  Telavancin.

Authors:  G Ralph Corey; Martin E Stryjewski; Wim Weyenberg; Uma Yasothan; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2009-12       Impact factor: 84.694

6.  Fluorescence microscopy demonstrates enhanced targeting of telavancin to the division septum of Staphylococcus aureus.

Authors:  Christopher S Lunde; Charles H Rexer; Stephanie R Hartouni; Sabine Axt; Bret M Benton
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

7.  Comparative mechanistic studies of brilacidin, daptomycin, and the antimicrobial peptide LL16.

Authors:  Bruk Mensa; Gabriella L Howell; Richard Scott; William F DeGrado
Journal:  Antimicrob Agents Chemother       Date:  2014-06-16       Impact factor: 5.191

8.  Membrane disruption by antimicrobial fatty acids releases low-molecular-weight proteins from Staphylococcus aureus.

Authors:  Joshua B Parsons; Jiangwei Yao; Matthew W Frank; Pamela Jackson; Charles O Rock
Journal:  J Bacteriol       Date:  2012-07-27       Impact factor: 3.490

Review 9.  Newer antibacterial drugs for a new century.

Authors:  Gina Devasahayam; William M Scheld; Paul S Hoffman
Journal:  Expert Opin Investig Drugs       Date:  2010-02       Impact factor: 6.206

10.  Telavancin.

Authors:  Katherine A Lyseng-Williamson; Stephanie K A Blick
Journal:  Drugs       Date:  2009       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.